Part One: President-Elect Trump Told Robert F. Kennedy Jr. to “Go Wild on Health.” What Might That Mean for the FDA?

President-elect Trump’s nominees for HHS Secretary, FDA, NIH, CMS and CDC promise to “shake things up” for pharmaceutical, medical device and food companies. What do these nominees have in mind, and what does it mean for affected industries? What strategies should companies be evaluating now to protect their businesses? What do investors need to know?

Hear from Polsinelli’s seasoned FDA practitioners and special guest, Wayne Pines for a look ahead on these topics and more!

Agenda

• What should we expect from Dr. Marty Makary, FDA Commissioner nominee, and the new top staff he will bring in?
• What policies might these nominees pursue?
• How should companies interact with the FDA?
• How will the loss of Chevron deference affect future FDA decisions? Will existing product approvals be jeopardized? What role will litigation play?